Last reviewed 2026-05-21 · How we verify

Loftran (KETAZOLAM)

Phase 2 active Small molecule ✓ Verified May 2026

Loftran (generic name: KETAZOLAM) is a ketazolam drug. It is currently in Phase 2 development.

Loftran works by enhancing the activity of a neurotransmitter called gamma-aminobutyric acid (GABA) in the brain.

Loftran is a small molecule with the synonyms ANSEREN, ANSIETEN, ANXON, CONTAMEX, KETAZOLAM, and KETAZOLAM.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	KETAZOLAM
Drug class	ketazolam
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of GABA like a brake pedal in a car. When GABA is released, it helps slow down or calm the activity in the brain. Loftran helps increase the amount of GABA available, which can lead to a calming effect and relief from anxiety or other conditions it may be used to treat.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Loftran CI brief — competitive landscape report
Loftran updates RSS · CI watch RSS

Frequently asked questions about Loftran

What is Loftran?

Loftran (KETAZOLAM) is a ketazolam drug.

How does Loftran work?

Loftran works by enhancing the activity of a neurotransmitter called gamma-aminobutyric acid (GABA) in the brain.

What is the generic name of Loftran?

KETAZOLAM is the generic (nonproprietary) name of Loftran.

What drug class is Loftran in?

Loftran belongs to the ketazolam class. See all ketazolam drugs at /class/ketazolam.

What development phase is Loftran in?

Loftran is in Phase 2.

Drug class: All ketazolam drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing